CLINUVEL Pharmaceuticals (ASX:CUV) has presented new evidence of its lead therapy SCENESSE (afamelanotide) delivering visible and lasting repigmentation in patients with vitiligo, one of the world’s most common pigmentary disorders. …
CLINUVEL’s SCENESSE demonstrates promising results in vitiligo patients
September 21, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Prescription medicines at the centre of Trump’s 'Great Healthcare Plan'
January 18, 2026 - - Latest News -
Boehringer Ingelheim again recognised as a top employer across Australia and New Zealand
January 18, 2026 - - Latest News -
The quiet and steady privatisation of this critical public health program
January 18, 2026 - - Latest News -
AbbVie to consolidate Sydney operations with move to CBD headquarters
January 15, 2026 - - Latest News -
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News